Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lenvatinib + MK-4280A |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lenvatinib | Lenvima | E7080 | FGFR Inhibitor (Pan) 26 KIT Inhibitor 57 PDGFR Inhibitor (Pan) 30 RET Inhibitor 53 VEGFR Inhibitor (Pan) 36 | Lenvima (lenvatinib) inhibits VEGFR, FGFR, PDGFR, KIT, and RET, and suppresses cell proliferation and angiogenesis (PMID: 21781317, PMID: 25295214, PMID: 17943726). Lenvima (lenvatinib) is FDA approved for use in patients with radioactive iodine-refractory differentiated thyroid cancer, unresectable hepatocellular carcinoma, in combination with Keytruda (pembrolizumab) as first line, or with Afinitor (everolimus) for renal cell carcinoma, and in combination with Pembrolizumab for endometrial carcinoma that is not MSI-H or dMMR (FDA.gov). |
MK-4280A | MK4280A|MK 4280A | Immune Checkpoint Inhibitor 149 LAG3 Antibody 18 PD-L1/PD-1 antibody 122 | MK-4280A is a coformulation of MK-4280 and Pembrolizumab, which potentially induces antitumor activity (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3584). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06036836 | Phase II | Lenvatinib + Pembrolizumab Lenvatinib + MK-4280A MK-4280A Pembrolizumab | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | Recruiting | USA | TUR | NLD | ITA | FRA | DEU | CAN | AUS | 2 |
NCT04626479 | Phase Ib/II | Lenvatinib + MK-1308A Lenvatinib + MK-4280A Lenvatinib + Pembrolizumab Belzutifan + Lenvatinib + Pembrolizumab | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | Active, not recruiting | USA | POL | NZL | NLD | ISR | HUN | GBR | FRA | ESP | CAN | AUS | 3 |